Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Eli Lilly is a pharma player, but it offers the growth of a tech stock thanks to its weight loss drugs portfolio. The weight ...

During the most recent episode of Mad Money, Jim Cramer opened the show by emphasizing just how much American companies ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research ...

Regeneron Pharmaceuticals, Inc. REGN is looking to make inroads in the lucrative obesity market. The company recently entered ...

Many people use the Fortune 500, our annual list of America’s largest companies that was published this week, as a starting ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

China has leaped from fast follower to global pioneer in drug discovery and development. We believe that Chinese companies ...

Explore the booming PTSD therapeutics market, projected to grow from $1.2 billion in 2024 to $5.4 billion by 2034 at a 15.8% CAGR. Key drivers includ ...

Breakingviews provides financial professionals with unique agenda-setting insight on the major financial news stories as they ...

Erste Group has downgraded Eli Lilly from a buy to a hold rating due to concerns about its earnings forecast. Despite 36.38% ...